Every time the U.S. tries to rein in rising drug prices, we hear the same thing from pharma: Stymie our profits, and you’ll get less innovation and fewer breakthrough treatments. Does the evidence back up this constant refrain?Guests:Chaitan Khosla, Director of Stanford ChEM-HCraig Garthwaite, Associate Professor of Strategy, Kellogg School of Management at Northwestern UniversityStacie Dusetzina, Associate Professor of Health Policy, Vanderbilt UniversityCheck out the research for yourself and learn more on our website: http://bit.ly/tradeoffsep8  As they say in health care, there’s no such thing as a free podcast. Support our show: https://tradeoffs.org/donate Follow us on Twitter: https://twitter.com/tradeoffspod  Hosted on Acast. See acast.com/privacy for more information.

Ver todos los episodios